ToxPro Program


Many promising drugs never reach their full potential due to their harmful side effects, which in many cases are due to their interaction with proteins other than those with which they were designed to interact, triggering an undesired cellular effect.

HK Pharmaceuticals addresses this industry challenge with its ToxPro program, using its CCMS™ technology to unravel the cause of toxic side effects at the protein level. In this application, proprietary Capture Compounds are used to identify and isolate proteins that interact with drugs. Once those proteins that act as targets leading to a positive therapeutic effect have been distinguished from the ‘non-targets’ leading to side effects, the drug is chemically re-engineered to optimize its interactions with only the desired target.